Next Article in Journal / Special Issue
Newborn Sickle Cell Disease Screening Using Electrospray Tandem Mass Spectrometry
Previous Article in Journal / Special Issue
Utilising the ‘Getting to Outcomes®’ Framework in Community Engagement for Development and Implementation of Sickle Cell Disease Newborn Screening in Kaduna State, Nigeria
Article Menu

Export Article

Open AccessReview
Int. J. Neonatal Screen. 2018, 4(4), 34; https://doi.org/10.3390/ijns4040034

Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening

1
PATH, 2201 Westlake Ave, Suite 200, Seattle, WA 98121, USA
2
Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 68/30 Bantung Road, PO Box 46 Mae Sot, Tak 63110, Thailand
3
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road campus, Roosevelt Drive, Oxford OX3 7FZ, UK
4
Eijkman Institute, Jalan Diponegoro 69, Jakarta 10430, Indonesia
*
Author to whom correspondence should be addressed.
Received: 1 October 2018 / Revised: 13 November 2018 / Accepted: 14 November 2018 / Published: 19 November 2018
  |  
PDF [489 KB, uploaded 19 November 2018]
  |  

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked genetic disorder, is associated with increased risk of jaundice and kernicterus at birth. G6PD deficiency can manifest later in life as severe hemolysis, when the individual is exposed to oxidative agents that range from foods such as fava beans, to diseases such as typhoid, to medications such as dapsone, to the curative drugs for Plasmodium (P.) vivax malaria, primaquine and tafenoquine. While routine testing at birth for G6PD deficiency is recommended by the World Health Organization for populations with greater than 5% prevalence of G6PD deficiency and to inform P. vivax case management using primaquine, testing coverage is extremely low. Test coverage is low due to the need to prioritize newborn interventions and the complexity of currently available G6PD tests, especially those used to inform malaria case management. More affordable, accurate, point-of-care (POC) tests for G6PD deficiency are emerging that create an opportunity to extend testing to populations that do not have access to high throughput screening services. Some of these tests are quantitative, which provides an opportunity to address the gender disparity created by the currently available POC qualitative tests that misclassify females with intermediate G6PD activity as normal. In populations where the epidemiology for G6PD deficiency and P. vivax overlap, screening for G6PD deficiency at birth to inform care of the newborn can also be used to inform malaria case management over their lifetime. View Full-Text
Keywords: glucose-6-phosphate dehydrogenase; G6PD deficiency; point-of-care; diagnostics; malaria; Plasmodium vivax glucose-6-phosphate dehydrogenase; G6PD deficiency; point-of-care; diagnostics; malaria; Plasmodium vivax
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Anderle, A.; Bancone, G.; Domingo, G.J.; Gerth-Guyette, E.; Pal, S.; Satyagraha, A.W. Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening. Int. J. Neonatal Screen. 2018, 4, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top